191 related articles for article (PubMed ID: 36447254)
1. Blocking lncRNA-SNHG16 sensitizes gastric cancer cells to 5-Fu through targeting the miR-506-3p-PTBP1-mediated glucose metabolism.
Ding Y; Gao S; Zheng J; Chen X
Cancer Metab; 2022 Nov; 10(1):20. PubMed ID: 36447254
[TBL] [Abstract][Full Text] [Related]
2. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis.
Xu J; Xu Y; Ye G; Qiu J
J Chemother; 2023 Oct; 35(6):527-538. PubMed ID: 36548909
[TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA HAGLR sponges miR-338-3p to promote 5-Fu resistance in gastric cancer through targeting the LDHA-glycolysis pathway.
Hu J; Huang L; Ding Q; Lv J; Chen Z
Cell Biol Int; 2022 Feb; 46(2):173-184. PubMed ID: 34658120
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HCG11 promotes 5-FU resistance of colon cancer cells through reprogramming glucose metabolism by targeting the miR-144-3p-PDK4 axis.
Cui Z; Wang Q; Deng MH; Han QL
Cancer Biomark; 2022; 34(1):41-53. PubMed ID: 34542064
[TBL] [Abstract][Full Text] [Related]
5. LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p.
Hua G; Zeng ZL; Shi YT; Chen W; He LF; Zhao GF
Pharmacology; 2021; 106(9-10):498-508. PubMed ID: 34352791
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR sensitizes 5-Fu-resistant colon cancer cells through modification of the lncRNA-FGD5-AS1-miR-330-3p-Hexokinase 2 axis.
Gao SJ; Ren SN; Liu YT; Yan HW; Chen XB
Mol Ther Oncolytics; 2021 Dec; 23():14-25. PubMed ID: 34589581
[TBL] [Abstract][Full Text] [Related]
7. LncRNA DLEU2 contributes to Taxol resistance of gastric cancer cells through regulating the miR-30c-5p-LDHA axis.
Xiang W; Zhang B; Li H
J Chemother; 2024 Feb; 36(1):49-60. PubMed ID: 37161284
[TBL] [Abstract][Full Text] [Related]
8. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.
Li LQ; Pan D; Chen Q; Zhang SW; Xie DY; Zheng XL; Chen H
Cell Physiol Biochem; 2018; 47(4):1533-1545. PubMed ID: 29940566
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of lncRNA-NEAT1 sensitizes 5-Fu resistant cervical cancer cells through de-repressing the microRNA-34a/LDHA axis.
Shao X; Zheng X; Ma D; Liu Y; Liu G
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 33645623
[TBL] [Abstract][Full Text] [Related]
10. SNHG16 promotes tumorigenesis and cisplatin resistance by regulating miR-338-3p/PLK4 pathway in neuroblastoma cells.
Xu Z; Sun Y; Wang D; Sun H; Liu X
Cancer Cell Int; 2020; 20():236. PubMed ID: 32536824
[TBL] [Abstract][Full Text] [Related]
11. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
Yu L; Chen D; Song J
Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
[TBL] [Abstract][Full Text] [Related]
12. SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p.
Bao J; Zhang S; Meng Q; Qin T
Neurochem Res; 2020 Apr; 45(4):825-836. PubMed ID: 31919621
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA SNHG16 promotes lipopolysaccharides-induced acute pneumonia in A549 cells via targeting miR-370-3p/IGF2 axis.
Zhang J; Mao F; Zhao G; Wang H; Yan X; Zhang Q
Int Immunopharmacol; 2020 Jan; 78():106065. PubMed ID: 31841752
[TBL] [Abstract][Full Text] [Related]
14. Overexpressing lncRNA
Xu F; Zha G; Wu Y; Cai W; Ao J
Onco Targets Ther; 2018; 11():8855-8863. PubMed ID: 30573973
[TBL] [Abstract][Full Text] [Related]
15. LncRNA SNHG16 Functions as an Oncogene by Sponging MiR-135a and Promotes JAK2/STAT3 Signal Pathway in Gastric Cancer.
Wang X; Kan J; Han J; Zhang W; Bai L; Wu H
J Cancer; 2019; 10(4):1013-1022. PubMed ID: 30854107
[TBL] [Abstract][Full Text] [Related]
16. LncRNA SNHG16 induced by TFAP2A modulates glycolysis and proliferation of endometrial carcinoma through miR-490-3p/HK2 axis.
Zhang G; Ma A; Jin Y; Pan G; Wang C
Am J Transl Res; 2019; 11(11):7137-7145. PubMed ID: 31814916
[TBL] [Abstract][Full Text] [Related]
17. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
[TBL] [Abstract][Full Text] [Related]
18. Silencing of LncRNA SNHG16 Downregulates Cyclin D1 (CCND1) to Abrogate Malignant Phenotypes in Oral Squamous Cell Carcinoma (OSCC) Through Upregulating miR-17-5p.
Wang Q; Han J; Xu P; Jian X; Huang X; Liu D
Cancer Manag Res; 2021; 13():1831-1841. PubMed ID: 33654431
[TBL] [Abstract][Full Text] [Related]
19. LncRNA SNHG16 drives proliferation, migration, and invasion of hemangioma endothelial cell through modulation of miR-520d-3p/STAT3 axis.
Zhao W; Fu H; Zhang S; Sun S; Liu Y
Cancer Med; 2018 Jul; 7(7):3311-3320. PubMed ID: 29845747
[TBL] [Abstract][Full Text] [Related]
20. Silencing LncRNA SNHG16 suppresses the diabetic inflammatory response by targeting the miR-212-3p/NF-κB signaling pathway.
Huang L; Xiong S; Liu H; Zhang R; Wu Y; Hu X
Diabetol Metab Syndr; 2023 Jun; 15(1):119. PubMed ID: 37280692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
